Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jcem.84.5.5677-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical treatment of acromegaly - When the tumor size matters: A narrative review.
Growth Horm IGF Res
October 2024
Clinic for Neurosurgery, University Clinical Center of Serbia, Dr Koste Todorovica 4, 11000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.
Medical treatment of acromegaly is generally positioned as a second line of treatment after pituitary adenoma surgery. With the rising availability and variety of medications for acromegaly increases our understanding of their effectiveness and safety. Volume of the published data on the impact of medical therapy on biochemical control of acromegaly, contrasts a relative lack of publications which comprehensively address pituitary tumor alterations under different drug modalities.
View Article and Find Full Text PDFPerioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. Comment on Br J Anaesth 2024; 132: 644-8.
Br J Anaesth
October 2024
Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Case Commentary: Extending our therapeutic range against multidrug-resistant .
Antimicrob Agents Chemother
August 2024
Division of Infectious Diseases, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Article Synopsis
- Deep-seated fungal infections often require prolonged antifungal treatments due to resistance issues.
- The article by Ponta et al. explores the use of rezafungin, a new long-acting antifungal, for extended therapy.
- The findings suggest that rezafungin could be a viable option for long-term treatment of infections resistant to standard antifungal medications.
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
Eur Respir J
June 2024
University of Otago Wellington, Wellington, New Zealand.
https://bit.ly/4aVFrNH
View Article and Find Full Text PDFRNA therapeutics to control fibrinolysis: review on applications in biology and medicine.
J Thromb Haemost
August 2024
Blood Research Institute, Versiti Wisconsin, Milwaukee, Wisconsin, USA; Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada; Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada; Departments of Surgery, Biochemistry, Biomedical Engineering, and Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Electronic address:
Article Synopsis
- - Regulation of fibrinolysis is crucial for normal blood clotting, as imbalances can lead to either blood clots (thrombosis) or excessive bleeding.
- - Various proteins involved in this process are potential targets for treatment, but effective inhibitors are currently lacking.
- - Advances in RNA-based technologies offer promising methods to control protein expression and could lead to innovative therapies for managing blood clotting issues by using RNA agents and efficient delivery systems.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!